AlloVir suspends ATM equity program; terminates prospectus supplement with SVB

Kalaris Therapeutics, Inc.

Notified SVB Securities on June 21, 2023 to suspend and terminate the ATM prospectus supplement.
No sales of common stock will be made under the Sales Agreement until a new prospectus supplement or registration statement is filed.
Sales Agreement dated August 6, 2021 remains in full force and effect except for the terminated supplement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.